BRIEF-Roche Says Satralizumab Added To Baseline Therapy Reduced Risk Of Relapse [Reuters]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Reuters
BRIEF-Roche Says Satralizumab Added To Baseline Therapy Reduced Risk Of Relapse | Reuters 1 Min Read Oct 15 (Reuters) - Roche Holding AG: * CHUGAI PRESENTS RESULTS FROM PHASE III STUDY OF SATRALIZUMAB IN NMOSD AT ECTRIMS 2018 * SATRALIZUMAB ADDED TO BASELINE THERAPY SIGNIFICANTLY REDUCED RISK OF RELAPSE * RESULTS WERE PRESENTED AT ECTRIMS CONGRESS HELD IN BERLIN FROM OCTOBER 10 TO 12 Source text for Eikon: [ bit.ly/2EmibNS ] Further company coverage: (Reporting by Berlin Speed Desk) All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. © 2018 Reuters. All Rights Reserved. BRIEF-Roche Says Satralizumab Added To Baseline Therapy Reduced Risk Of Relapse Oct 15 (Reuters) - Roche Holding AG: * CHUGAI PRESENTS RESULTS FROM PHASE III STUDY OF SATRALIZUMAB IN NMOSD AT ECTRIMS 2018 * SATRALIZUMAB ADDED TO BASELINE THERAPY SIGNIFICANTLY REDUCED RISK OF RELAPSE * RESULTS WERE PRESENTED AT ECTRIMS CONGRESS HELD IN BERLIN FROM OCTOBER 10 TO 12 S
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Roche's subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS [Yahoo! Finance]Yahoo! Finance
- Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MSBusiness Wire
- Genentech's Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study [Yahoo! Finance]Yahoo! Finance
- Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO StudyBusiness Wire
- [Ad hoc announcement pursuant to Art. 53 LR] Roche's Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study [Yahoo! Finance]Ad hoc announcement pursuant to Art. 53 LR